Manhattan Scientifics MHTX · USD

Its shares trade under the ticker MHTX. It has been listed since 24 May 2000. In the fiscal year to 31 December 2022, it reported revenue of $50,000 and a net loss of $2.7m. At that date it held total assets of $1.0m and shareholders' equity of −$1.7m.

Manhattan Scientifics, Inc. focuses on technology transfer and commercialization of transformative technologies. The company is headquartered in New York City, New York. The company went IPO on 2000-05-24. The firm is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The firm has two subsidiaries, both focused on nanotechnology applications in medicine: Metallicum, Inc. and Senior Scientific LLC. The firm's bioimaging and nanomagnetic detection systems have been developed to detect cancer and other diseases earlier and with specificity. The company has developed hardware and software for the sensitive detection of nanomagnetic particles that can be linked to antibodies for the detection and treatment of cancer and other human diseases, all without the use of ionizing radiation or large magnetic fields. Its technologies make possible the earlier detection of cancer in vivo, and the ability to analyze biopsies with sensitivity.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Marvin MaslowChairman of the Board, since 1998$861,667
• Mr. Emmanuel TsoupanariasPresident, Chief Executive Officer, Director, since 2015$186,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.